As I said, these smaller ones have a historical device component not present in the major “pure pharma/bio-science” companies we covered over this past weekend. So they seek input on laws that generally don’t concern pure pharma (like infusion pumps and cardiovascular implants).

And Baxter — with important operational (and candidly, regulatory) challenges of its own, has greatly reduced its lobby spend over the past two years. That is more a function of deploying the dollars where they’ll do the most good in the near term, than much of anything else. Here’s that run-down, on the $440,000 of spend in the past quarter:

…Issues relating to drug pricing, home dialysis expansion, and ESRD reimbursement for Hemodialysis….

Issues related to pharmaceutical pricing; Legislation to incentivize new technology for innovation in home dialysis (no current bill number)….

Issues relating to 340B Drug pricing, and device sterilization; Issues relating to safe mobility and issues relating to diabetic retinopathy; Issues relating to pandemic preparedness act; H. Res. 550 and H.R. 4421; Issues related to artificial intelligence technology in healthcare….

Issues related to increasing funding for Strategic National Stockpile; Labor, Health, and Human Services appropriations….

Taxation of multinational companies; Monitor tax reform proposal relating to corporate tax policies….

Now you know… be excellent to one another, now and always.

नमस्ते